Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01925794 · ClinicalTrials.gov registry record · NA

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

A NA study of Coronary Artery Disease, sponsored by CeloNova BioSciences.

Completed
Registry status
NA
Development phase
296
Enrollment target
20
Study locations

NCT01925794: Completed NA study of Coronary Artery Disease, sponsored by CeloNova BioSciences.

NCT01925794 is a NA study of Coronary Artery Disease that has completed, run by CeloNova BioSciences. The registered enrollment target is 296 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01925794, a NA study of Coronary Artery Disease, has completed, sponsored by CeloNova BioSciences.

COMPLETED
Registry status
NA
Development phase
296 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and Outside United States (OUS). This study will enroll patients with symptomatic ischemic heart disease due to a single de novo lesion contained within a native coronary artery with reference vessel diameter between 2.5 mm and 4.0 mm and lesion length ≤ 24 mm that is amenable to percutaneous coronary intervention (PCI) and stent deployment. All patients will be followed at 30 days, 6 months, 9 months, 1 year and annually for 5 years post index stenting procedure.

Primary Outcome

TVF defined as cardiac death, target vessel myocardial infarction (MI \[Q wave or non-Q wave, ARC definition\], or clinically driven target vessel revascularization (TVR) by percutaneous or surgical methods within 270 days post-procedure.

Conditions Studied

Interventions

  • DEVICE COBRA PzF

Study Locations (20)

Texas

  • Cardiology Consultants of Texas - Dallas
  • Plaza Medical Center - Fort Worth
  • Houston Methodist Hospital - Houston
  • Texas Cardiac Center - Lubbock
  • The Heart Hospital Baylor Plano - Plano
  • San Antonio Endovascular & Heart Institute - San Antonio
  • Tyler Cardiovascular Consultants - Tyler

New York

  • St Joseph's Hospital - Liverpool
  • Lenox Hill Hospital - New York
  • Mount Sinai Hospital - New York

California

  • Bakersfield Memorial Hospital - Bakersfield

Florida

  • Mt Sinai Medical Center - Miami Beach

Georgia

  • Emory University Hospital - Atlanta

Indiana

  • Heart Center of Indiana - Indianapolis

Louisiana

  • Louisiana Heart Hospital - Lacombe

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Trial Details

FieldValue
Enrollment Target 296 participants
Start Date 2013-08-21
Est. Completion 2020-03-02
Phase NA
CeloNova BioSciences

1 total trials

What the finished NCT01925794 record still lists

NCT01925794 is an interventional study that assigns participants to a tested intervention. The registered 296 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which COBRA PzF is the first listed.

NCT01925794 names 20 study sites across 12 states, led by Texas, New York, California.

Frequently Asked Questions

What is clinical trial NCT01925794 about?

NCT01925794 is a clinical study titled "COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT". This is a prospective, multi-center, non-randomized, single arm clinical trial that will be conducted at up to 40 sites in the United States and Outside United States (OUS). This study will enroll patients with symptomatic ischemic heart disease due to a single de novo lesion contained within a nati...

What is the current status of trial NCT01925794?

This trial is currently completed. It is a NA study. The enrollment target is 296 participants. The study started on 2013-08-21. Estimated completion is 2020-03-02.

What conditions does trial NCT01925794 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT01925794?

The interventions under investigation include: COBRA PzF (DEVICE).

Who is sponsoring clinical trial NCT01925794?

This trial is sponsored by CeloNova BioSciences, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01925794 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01925794's enrollment target sits among peer trials

296 105th of 219 higher than 115 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05563792 · 296 participants · NA

    Options for Pain Management Using Nonpharmacological Strategies

  • NCT06828445 · 296 participants · Phase 1

    Increasing Affordable Fruits and Vegetables for Families With Food Insecurity

  • NCT06920563 · 296 participants · NA

    Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education

  • NCT06309160 · 297 participants · NA

    COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01925794, the US trial registry maintained by the National Library of Medicine. NCT01925794 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.